Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498283 | 0.92 | CRHR1 (0.54) | CRHR1RAD52PABPC1 | |
| SCHEMBL4500640 | 0.92 | CRHR1 (0.47) | CRHR1AKR1C3AKR1C2KDM4E | |
| SCHEMBL4483814 | 0.90 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL4494259 | 0.87 | CRHR1 (0.44) | CRHR1RAD52 | |
| SCHEMBL4494321 | 0.84 | CRHR1 (0.44) | CRHR1AKR1C3AKR1C2KDM4E | |
| SCHEMBL4479812 | 0.82 | CRHR1 (0.39) | CRHR1TSPOKDM4E | |
| SCHEMBL4489221 | 0.82 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL4499176 | 0.81 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL4482511 | 0.81 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL4492009 | 0.81 | CRHR1 (0.36) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | claimed |
| EP-1961745-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | claimed |
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1961745-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRHR1, NR3C1, CNR1 | CRHR1 1/4885RAD52 2839/4885PABPC1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.